Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Primary Biliary Cholangitis Therapeutics Market: By Type: OCALIVA, Ursodiol, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; SWOT Analysis; Porter’s Five Forces Analysis; EMR’s Key Indicators for Demand; Competitive Landscape; Industry Events and Developments
Global Primary Biliary Cholangitis Therapeutics Market Outlook
The global primary biliary cholangitis therapeutics market is expected to grow at a CAGR of about 10.5% in the forecast period of 2022-2027. One of the key drivers for the industry growth is the increasing awareness campaigns to mitigate more complications in the primary biliary cholangitis indicator.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Primary biliary cholangitis refers to a rare chronic disease of the liver, formerly referred to as primary biliary cirrhosis, mainly characterized by the degradation of the biliary ducts, which contain bile acid from the skin. Even though the root cause of the disease has still not been established, worldwide work has shown that the disorder is autoimmune in nature. The progression of this disease contributes to the destructive deposition of bile acid, which causes serious liver damage. The disease mainly affects middle-aged women. The lack of a conclusive treatment for primary biliary cholangitis (PBC) offers an incredibly lucrative business opportunity.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised based on its type into:
- OCALIVA
- Ursodiol
- Others
The EMR report looks into the regional markets of primary biliary cholangitis therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The increasing awareness campaigns aimed at reducing any more complications in the primary indication of cholangitis are among the main drivers of the industry growth. The asymptomatic nature of the condition, in most cases, leads to a delay in diagnosis. Moreover, the majority of the population is not aware of the signs of the disease. Many sellers took advantage of this and began to organize awareness campaigns. Many non-profit organizations also run prevention campaigns and fund research into new disease therapies. Such factors will expand the sales of primary biliary cholangitis therapies and enable the market to grow.
Regenerative therapy study gains traction as an experimental liver transplant phase triggers a problem for patients following surgery. However, owing to the chronic nature of the disease, there is currently no treatment for the symptom other than a liver transplant. It allows researchers to perform a stem cell transplantation test that can replace those cells destroyed in the bile duct. This current research should have a positive effect on the overall growth of the market.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global primary biliary cholangitis therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Glenmark Pharmaceuticals Ltd.
- Abbott Laboratories
- AbbVie Inc.
- Others
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Region |
| Breakup by Type | OCALIVA, Ursodiol, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Intercept Pharmaceuticals, Inc., Novartis AG, Glenmark Pharmaceuticals Ltd., Abbott Laboratories and AbbVie Inc., Others. |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Primary Biliary Cholangitis Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Primary Biliary Cholangitis Therapeutics Historical Market (2017-2021)
8.3 Global Primary Biliary Cholangitis Therapeutics Market Forecast (2022-2027)
8.4 Global Primary Biliary Cholangitis Therapeutics Market by Type
8.4.1 OCALIVA
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Ursodiol
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Others
8.5 Global Primary Biliary Cholangitis Therapeutics Market by Region
8.5.1 Market Share
8.5.1.1 North America
8.5.1.2 Europe
8.5.1.3 Asia Pacific
8.5.1.4 Latin America
8.5.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Intercept Pharmaceuticals, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Novartis AG
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Glenmark Pharmaceuticals Ltd.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Abbott Laboratories
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 AbbVie Inc.
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Primary Biliary Cholangitis Therapeutics Market: Key Industry Highlights, 2016 and 2026
2. Global Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Type (USD Billion), 2017-2021
3. Global Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Type (USD Billion), 2022-2027
4. Global Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
5. Global Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
6. North America Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
7. North America Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
8. Europe Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
9. Europe Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
10. Asia Pacific Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11. Asia Pacific Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Latin America Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Latin America Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Middle East and Africa Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Middle East and Africa Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Global Primary Biliary Cholangitis Therapeutics Market Structure
Key Questions Answered in the Report
The global primary biliary cholangitis therapeutics market is projected to grow at a CAGR of 10.5% between 2021 and 2026.
The major drivers of the industry, such as the increasing awareness campaigns aimed at reducing any more complications, asymptomatic nature of the condition, unawareness of the symptoms of the disease among the population, and increasing funding of research into new disease therapies, are all expected to aid the market growth.
The key market trend guiding the growth of the primary biliary cholangitis therapeutics industry include the ongoing research to perform a stem cell transplantation test that can replace those cells destroyed in the bile duct.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
OCALIVA and ursodiol, among others, are the major types of primary biliary cholangitis therapeutics in the industry.
The major players in the industry are Intercept Pharmaceuticals, Inc., Novartis AG, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, and AbbVie Inc., among others.
Analyst Review
The global primary biliary cholangitis therapeutics market is being driven by the growing awareness campaigns. Aided by the increased research funding in the industry, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 10.5%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the industry can be segmented into OCALIVA, ursodiol, and others. The major regional markets for primary biliary cholangitis therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Intercept Pharmaceuticals, Inc., Novartis AG, Glenmark Pharmaceuticals Ltd., Abbott Laboratories and AbbVie Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global neurological disease treatment market was driven by the rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer...
The global hepatic disease treatment market attained a value of nearly USD 21.97 billion, driven by the rise in the prevalence of liver diseases. Aided by the increasing alcohol consumption and growin...
The global autism spectrum disorder therapeutics market attained a value of about USD 3.33 billion in 2021, driven by the rising research and development projects fostered by the government and market...
The global glaucoma therapeutics market attained a value of USD 7.24 billion in 2021, driven by the rising prevalence of glaucoma worldwide. Aided by the favourable reimbursement policies and growing ...
The global central nervous system treatment market was driven by the increasing incidence of neurological disorders in the historical period. Aided by the launch of new prospective products and pipeli...
NEWSLETTER